author-photo

Pablo Lee

Eli Lilly and Company

34

Papers

246

Citations

Citation Trend

Filter By

Papers (25) Sort By

Journal Conference Others

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy

2020
Show All
- Source
- Cite
- Save
Citations (1)
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology

2019 Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (14)
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting

2018 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (17)
Olaratumab for the treatment of patients (pts) with advanced/metastatic soft tissue sarcoma (STS): Treatment patterns in the United States (US) during the first year post-approval.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer

2018 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (7)
Étude randomisée de phase 1B/3 sur l’erlotinib + le ramucirumab dans les CBNPC de stade IV non traité présentant une mutation de l’EGFR : résultats de la phase 1B

2018 Revue Des Maladies Respiratoires
Show All
- Source
- Cite
- Save
Citations (0)
P2.06-016 Phase 2 Study of Ramucirumab plus Weekly Docetaxel in Stage IV NSCLC Following Progression after Platinum-Based Chemotherapy: Topic: Phase II + NK

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer

2017 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (24)
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial

2017 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (5)
Multizentrische, randomisierte Doppelblindstudie mit Erlotinib plus Ramucirumab oder plus Plazebo bei metastasiertem nichtkleinzelligen Lungenkarzinom (NCSLC) mit EGFR-Mutation

2017 Pneumologie
Show All
- Source
- Cite
- Save
Citations (0)